Effect of intensive lipid-lowering therapy on inflammatory factors and fibrinolytic system in patients with acute cerebral infarction

• Main Authors: De-Ning Guan, Ya-nan Hu, Yang Zhang, Yun Luo
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2016-08-01
• Series: Journal of Hainan Medical University
• Subjects: Atorvastatin; Intensive lipid-lowering; Acute cerebral infarction; Inflammatory factors
• Online Access: http://www.hnykdxxb.com/PDF/201616/38.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To investigate the effects of atorvastatin calcium on the inflammatory factors and fibrinolytic system in patients with acute cerebral infarction. Methods: A total of 170 inpatients with acute cerebral infarction in Neurological department of our hospital between December 2014 and December 2015 were selected as Subjects in the study, and randomly divided into intensive lipid-lowering therapy group (85 cases) and control group (85 cases). before the treatment, FPG, HbA1c (%), TG, TCH and LDL-C, HDL-C in patients were detected. hs-CRP, IL-6, IL-8, IL-10, TNF-α in serum, and PAI-1, t-PA, FIB in plasma were detected and compared between before treatment and 8 weeks after the treatment. Results: patients with acute cerebral infarction in intensive lipid-lowering therapy group and control group showed no significant difference in inflammatory factors (hs-CRP, IL-6, IL-8, IL- 10, TNF-α) and fibrinolytic system (PAI-1, t-PA, FIB) before treatment. After eight weeks of treatment, hs-CRP, IL-6, IL-8, TNF-α, PAI-1 and FIB in patients in both groups were lower than that before treatment, and had statistical difference. IL-10, t-PA was increased than that before treatment and also had significant difference. In intensive lipid-lowering therapy group, the variation ranges of hs-CRP, IL-6, IL-8, IL-10, TNF-α, PAI-1, t-PA and FIB were greater than that of the control group, and were statistically different. Conclusion: Atorvastatin calcium, the intensive lipid-lowering therapy, can reduce hs-CRP, IL-6, IL-8, TNF-a, PAI-1, FIB levels significantly in the acute cerebral infarction patients, and elevate levels of IL-10 and t-PA in serum. It has the effect on inhibiting inflammation and regulating the fibrinolytic activity.